Zimrin Ann B, Hess John R
Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Surgery. 2007 Oct;142(4 Suppl):S15-9. doi: 10.1016/j.surg.2007.06.022.
Voluntary blood donors are the source of all red cell, platelet, and unprocessed plasma products used in clinical medicine. Paid donors provide most of the raw plasma used in commercially processed plasma products, such as albumin and intravenous gamma globulin. Each year, less than 5% of the population donates blood, and almost half the units come from 1% of the population who are frequent donors. Pressures that affect the number of potential donors include changing demography and motivation. Pressures that affect the suitability of potential donors include endemic and emerging infectious diseases, drug and vaccine use, and behavioral factors. The net result of these pressures is increasing difficulty in finding enough acceptable donors. Demands on the current blood supply leave few resources and raw materials available for the development of newer, safer, and more effective therapeutic products. The development of recombinant coagulation proteins reduces the pressure on this limited supply of donated plasma, and reducing bleeding protects the supply of cellular blood and plasma-derived products.
自愿献血者是临床医学中所有红细胞、血小板和未加工血浆制品的来源。有偿献血者提供了商业加工血浆制品(如白蛋白和静脉注射用丙种球蛋白)中使用的大部分原料血浆。每年,不到5%的人口献血,几乎一半的献血单位来自1%的频繁献血者群体。影响潜在献血者数量的因素包括人口结构变化和献血动机。影响潜在献血者适用性的因素包括地方性和新出现的传染病、药物和疫苗使用以及行为因素。这些因素的最终结果是找到足够多合适献血者的难度越来越大。对当前血液供应的需求使得用于开发更新、更安全、更有效的治疗产品的资源和原材料所剩无几。重组凝血蛋白的开发减轻了对这种有限捐赠血浆供应的压力,而减少出血则保护了细胞血液和血浆衍生产品的供应。